Drugs / rV-CEA(6D)-TRICOM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00009958 | Nov 2000 → Apr 2010 | cancer of unknown primary site | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rV-CEA(6D)-TRICOM | “rV-CEA(6D)-TRICOM (recombinant vaccinia-CEA(6D)-B7.1/ICAM-1/LFA-3)” NCT00009958 ↗ |
| Known as | vCEA-TRI | “OUTLINE: This is a dose-escalation study of fowlpox-CEA-TRICOM (fCEA-TRI) vaccine and vaccinia-CEA-TRICOM (vCEA-TRI) vaccine.” NCT00009958 ↗ |
| Modality | Vaccine | “novel CEA-based vaccine” NCT00009958 ↗ |
| Route | Other | “Given intradermally” NCT00009958 ↗ |